Study finds use of cancer medications declines after withdrawal of accelerated approval
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsExpedited pathwaysMarket withdrawalPharmaceuticalsProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)